Clinician-initiated research on treating the host response to pandemic influenza

Human Vaccines and Immunotherapeutics

Volumn 14, Issue 3, 2018, Pages 790-795

  Fedson, David S ^a  

^a NONE   (France)

Author keywords

angiotensin receptor blockers; Ebola; host response; pandemic influenza; statins

Indexed keywords

ANGIOPOIETIN; ANGIOPOIETIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; GENERIC DRUG; INFLUENZA VACCINE;

ADULT RESPIRATORY DISTRESS SYNDROME; APOPTOSIS; AUTOPHAGY; CLINICAL EFFECTIVENESS; COMMUNITY ACQUIRED PNEUMONIA; EBOLA HEMORRHAGIC FEVER; HEALTH CARE PERSONNEL; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; IMMUNE RESPONSE; INFLUENZA A (H1N1); INFLUENZA A (H7N9); INFLUENZA A VIRUS (H1N1); MORTALITY RATE; NONHUMAN; NOTE; PANDEMIC INFLUENZA; PNEUMONIA; SEPSIS; VACCINATION; EPIDEMIC; IMMUNOLOGY; INFLUENZA; PANDEMIC;

DISEASE OUTBREAKS; DRUGS, GENERIC; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLUENZA VACCINES; INFLUENZA, HUMAN; PANDEMICS; PNEUMONIA; SEPSIS;

EID: 85033474877     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2017.1378292     Document Type: Note

References (43)

1. Starr I. Influenza in 1918: Recollections of the epidemic in Philadelphia. 1976. Ann Intern Med. 2006;145:138-40. PMID:16801626
2. Fedson DS. How will physicians respond to the next influenza pandemic? Clin Infect Dis. 2014;58:233-7. PMID:24145877
3. Sun LH. Outgoing CDC chief talks about agency's successes–and his greatest fear. The Washington Post, January 16, 2017 [accessed 2017May14]. https://www.washingtonpost.com/news/to-your-health/wp/2017/01/16/outgoing-cdc-chief-talks-about-the-agencys-successes-and-his-greatest-fear/?utm_term=.7565643f282c.
4. Lansbury LE, Smith S, Beyer W, Karamehic E, Pasic-Juhas E, Sikira H, Mateus A, Oshitani H, Zhao H, Beck CR, et al. Effectiveness of 2009 pandemic influenza A(H1N1) vaccines: A systematic review and meta-analysis. Vaccine. 2017;35:1996-2006. PMID:28302409
5. Borse RH, Shrestha SS, Fiore AE, Atkins CY, Singleton JA, Furlow C, Meltzer MI. Effects of vaccine program against pandemic influenza A(H1N1) virus, United States, 2009–2010. Emerg Infect Dis. 2013;19:439-48. PMID:23622679
6. US Department of Health and Human Services. Pandemic influenza plan. 2017 update [accessed 2017June20]. https://www.cdc.gov/flu/pandemic-resources/pdf/pan-flu-report-2017.pdf.
7. Wang X, Jiang H, Wu P, Uyeki TM, Feng L, Lai S, Wang L, Huo X, Xu K, Chen E, et al. Epidemiology of avian influenza A H7N9 virus in human beings across five epidemics in mainland China, 2013–17: An epidemiological study of laboratory-confirmed case series. Lancet Infect Dis. 2017;17:822-32. PMID:28583578
8. de Vries RP, Peng W, Grant OC, Thompson AJ, Zhu X, Bouwman KM, de la Pena ATT, van Breemen MJ, Ambepitiya Wickramasinghe IN, de Haan CAM, et al. Three mutations switch H7N9 influenza to human-type receptor specificity. PLoS Pathog. 2017;13:e1006390. PMID:28617868
9. World Health Organization. Report of a WHO informal consultation held in Geneva, Switzerland influenza vaccine response during the start of a pandemic influenza vaccine response during the start of a pandemic, 29 June-1 July, 2015 [accessed 2017May14]. apps.who.int/iris/bitstream/10665/207751/1/WHO_OHE_PED_GIP_2016.1_eng.pdf.
10. Røttingen JA, Gouglas D, Feinberg M, Plotkin S, Raghavan KV, Witty A, Draghia-Akli R, Stoffels P, Piot P. New vaccines against epidemic infectious diseases. N Engl J Med. 2017;376:610-3. PMID:28099066
11. Palache A, Abelin A, Hollingsworth R, Cracknell W, Jacobs C, Tsai T, Barbosa P,; IFPMA Influenza Vaccine Supply (IFPMA IVS) task force. Survey of distribution of seasonal influenza vaccine doses in 201 countries (2004–2015): The 2003 World Health Assembly resolution on seasonal influenza vaccination coverage and the 2009 influenza pandemic have had very little impact on improving influenza control and pandemic preparedness. Vaccine. 2017;35:4681-6.
12. Muthuri SG, Venkatesan S, Myles PR, Leonardi-Bee J, Al Khuwaitir TS, Al Mamun A, Anovadiya AP, Azziz-Baumgartner E, Báez C, Bassetti M, et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: A meta-analysis of individual participant data. Lancet Respir Med. 2014;2:395-404. PMID:24815805
13. Fedson DS. Meeting the challenge of influenza pandemic preparedness in developing countries. Emerg Infect Dis. 2009;15:365-71. doi:10.3201/eid1503.080857. PMID:19239746
14. Fedson DS. Treating influenza with statins and other immunomodulatory agents. Antiviral Res. 2013;99:417-35. doi:10.1016/j.antiviral.2013.06.018. PMID:23831494
15. Sugiyama MG, Armstrong SM, Wang C, Hwang D, Leong-Poi H, Advani A, Advani S, Zhang H, Szaszi K, Tabuchi A, et al. The Tie2-agonist Vasculotide rescues mice from influenza virus infection. Sci Rep. 2015;5:11030. doi:10.1038/srep11030. PMID:26046800
16. Ip WKE, Hoshi N, Shouval DS, Snapper S, Medzhitov R. Anti-inflammatory effect of IL-10 mediated by metabolic reprogramming of macrophages. Science. 2017;356:513-19.
17. Fedson DS. Treating emerging virus diseases: Lessons learned from sepsis, pneumonia, influenza and Ebola. Ann Transl Med. 2016;4:421. doi:10.21037/atm.2016.11.03. PMID:27942512
18. Ghosh CC, David S, Zhang R, Berghelli A, Milam K, Higgins SJ, Hunter J, Mukherjee A, Wei Y, Tran M, et al. Gene control of tyrosine kinase TIE2 and vascular manifestations of infections. Proc Natl Acad Sci U S A. 2016;113:2472-7. doi:10.1073/pnas.1519467113. PMID:26884170
19. Ghosh CC, Thamm K, Berghelli AV, Schrimpf C, Maski MR, Abid T, Milam KE, Rajakumar A, Santel A, Kielstein JT, et al. Drug repurposing screen identifies Foxo1-dependent angiopoietin-2 regulation in sepsis. Crit Care Med. 2015;43:e230-40. doi:10.1097/CCM.0000000000000993. PMID:25855898
20. Zinter MS, Spicer A, Orwoll BO, Alkhouli M, Dvorak CC, Calfee CS, Matthay MA, Sapru A. Plasma angiopoietin-2 outperforms other markers of endothelial injury in prognosticating pediatric ARDS mortality. Am J Physiol Lung Cell Mol Physiol. 2016;310:L224-31. doi:10.1152/ajplung.00336.2015. PMID:26660787
21. Hahn WO, Mikacenic C, Price BL, Harju-Baker S, Katz R, Himmelfarb J, Wurfel MM, Liles WC. Host derived biomarkers of inflammation, apoptosis, and endothelial activation are associated with clinical outcomes in patients with bacteremia and sepsis regardless of microbial etiology. Virulence. 2016;7:387-94. doi:10.1080/21505594.2016.1144003. PMID:26818467
22. Fedson DS. Pandemic influenza: A potential role for statins in treatment and prophylaxis. Clin Infect Dis. 2006;43:199-205. doi:10.1086/505116. PMID:16779747
23. Vandermeer ML, Thomas AR, Kamimoto L, Reingold A, Gershman K, Meek J, Farley MM, Ryan P, Lynfield R, Baumbach J, et al. Association between use of statins and mortality among patients hospitalized with laboratory-confirmed influenza virus infections: A multistate study. J Infect Dis. 2012;205:13-9. doi:10.1093/infdis/jir695. PMID:22170954
24. Laidler MR, Thomas A, Baumbach J, Kirley PD, Meek J, Aragon D, Morin C, Ryan PA, Schaffner W, Zansky SM, et al. Statin treatment and mortality: Propensity score-matched analyses of 2007–2008 and 2009–2010 laboratory-confirmed influenza hospitalizations. Open Forum Infect Dis. 2015;2:ofv028. doi:10.1093/ofid/ofv028. PMID:26034777
25. Fedson DS. Statins, influenza vaccination and influenza. J Infect Dis. 2017;215:484-5. PMID:27932610
26. Mortensen EM, Nakashima B, Cornell J, Copeland LA, Pugh MJ, Anzueto A, Good C, Restrepo MI, Downs JR, Frei CR, et al. Population-based study of statins, angiotensin II receptor blockers, and angiotensin-converting enzyme inhibitors on pneumonia-related outcomes. Clin Infect Dis. 2012;55:1466-73. doi:10.1093/cid/cis733. PMID:22918991
27. Mortensen EM, Pugh MJV, Anzueto A. Prior use of both a statin and ARB is associated with lower mortality for patients hospitalized with pneumonia. Abs. European Respiratory Society, London 3–7 September 2016.
28. Lee HY, Sakuma I, Ihm AH, Goh CW, Koh KK. Statins and renin-angiotensin system inhibitor combination treatment to prevent cardiovascular disease. Circ J. 2014;78:281-7. doi:10.1253/circj.CJ-13-1494. PMID:24401609
29. Fedson DS, Rordam OM. Treating Ebola patients: A “bottom up” approach using generic statins and angiotensin receptor blockers. Int J Infect Dis. 2015;36:80-4. doi:10.1016/j.ijid.2015.04.019. PMID:26143190
30. Rojek A, Horby P, Dunning J. Insights from clinical research completed during the west Africa Ebola virus disease epidemic. Lancet Infect Dis. 2017;9:e280-92. doi:10.1016/S1473-3099(17)30234-7. PMID:28461209
31. Hayden FG, Friede M, Bausch DG. Experimental therapies for Ebola virus disease: What have we learned? J Infect Dis. 2017;215:167-70. PMID:28073859
32. Vandenbroucke JP. In defense of case reports and case series. Ann Intern Med. 2001;134:330-4. doi:10.7326/0003-4819-134-4-200102200-00017. PMID:11182844
33. Glasziou P, Chalmers I, Rawlins M, McCulloch P. When are randomised trials unnecessary? Picking signal from noise. BMJ. 2007;334:349-51. doi:10.1136/bmj.39070.527986.68. PMID:17303884
34. National Academies of Sciences, Engineering, and Medicine. Integrating clinical research into epidemic response. The Ebola experience. Washington, DC: The National Academies Press. 2017. doi: 10.17226/24739.
35. Fedson DS. Observational studies help us understand how to treat pandemic influenza and other emerging virus diseases. J Emerg Crit Care Med. 2017;1:10.
36. Ahmed R, Oldstone MB, Palese P. Protective immunity and susceptibility to infectious diseases: Lessons from the 1918 influenza pandemic. Nat Immunol. 2007;8:1188-93. doi:10.1038/ni1530. PMID:17952044
37. Suber F, Kobzik L. Childhood tolerance of severe influenza: a mortality analysis in mice. Am J Physiol Lung Cell Mol Physiol. 2017. doi:10.1152/ajplung.00364.2017. PMID:28882815 [accessed 2017 September 10].
38. Soares MP, Teixeira L, Moita LF. Disease tolerance and immunity in host protection against infection. Nat Rev Immunol. 2017;17:83-96. doi:10.1038/nri.2016.136. PMID:28044057
39. Barsness KA, Bensard DD, Partrick DA, Calkins CM, Hendrickson RJ, McIntyre RC, Jr. Endotoxin induces an exaggerated interleukin-10 response in peritoneal macrophages of children compared with adults. J Pediatr Surg. 2004;39:912-5; discussion 912–5. doi:10.1016/j.jpedsurg.2004.02.009. PMID:15185224
40. Shin T, Kuboki S, Huber N, Eismann T, Galloway E, Schuster R, Blanchard J, Pritts TA, Lentsch AB. Activation of peroxisome proliferator-activated receptor-gamma during hepatic ischemia is age-dependent. J Surg Res. 2008;147:200-5. doi:10.1016/j.jss.2008.02.004. PMID:18498870
41. Baddeley M. Herding, social influences and behavioural bias in scientific research: Simple awareness of the hidden pressures and beliefs that influence our thinking can help to preserve objectivity. EMBO Rep. 2015;16:902-5. doi:10.15252/embr.201540637. PMID:26169390
42. World Health Organization. Research and development for potentially epidemic diseases. A blueprint for research and development preparedness and rapid research response 20 March 2017 [accessed 2017May28]. apps.who.int/gb/ebwha/pdf_files/WHA70/A70_10-en.pdf.
43. Baddeley M. Experts in policy land–Insights from behavioural economics on improving experts' advice for policy-makers. J Behav Econ Policy. 2017;1:27-31.